close

Fenwick Represents Stoke Therapeutics in $40 Million Series A Financing

January 09, 2018

​​Fenwick & West represented Stoke Therapeutics, Inc, an emerging biotechnology company working to increase gene expression to treat a wide array of severe genetic diseases, in its $40 million Series A financing. The Series A round was provided by founding investor Apple Tree Partners.

Stoke will use the funds to support the further advancement of multiple pre-clinical development programs. More information about Stoke’s $40 million Series A financing can be obtained from the company press release.

The Fenwick transaction team was led by corporate lawyers Alan Smith, Ashley Walter and Annie Omata.​